Glucocorticoid Therapy in COVID-19

Francesco Amati; Antonio Tonutti; John Huston; Charles S. Dela Cruz

doi:10.1055/s-0042-1759778

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2023; 44(01): 100-117
DOI: 10.1055/s-0042-1759778

Review Article

Glucocorticoid Therapy in COVID-19

Francesco Amati

¹Respiratory Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

,

Antonio Tonutti

²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

,

John Huston

³Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Critical Care and Sleep Medicine, Center for Pulmonary Infection Research and Treatment, Yale School of Medicine, New Haven, Connecticut

,

Charles S. Dela Cruz

³Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Critical Care and Sleep Medicine, Center for Pulmonary Infection Research and Treatment, Yale School of Medicine, New Haven, Connecticut

› Institutsangaben

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality in pandemic proportions. Inflammation in response to the infection contributes to the pathogenesis of pneumonia. This review will discuss prior studies on the use of glucocorticoids to treat respiratory infections, the rationale for the use glucocorticoids in COVID-19, and review of existing data. We will also highlight outstanding research questions for future studies.

Keywords

glucocorticoid - treatment - COVID-19

Volltext

Referenzen

References
1 Feldman C, Anderson R. Pneumonia as a systemic illness. Curr Opin Pulm Med 2018; 24 (03) 237-243
2 Mizgerd JP. Inflammation and pneumonia: why are some more susceptible than others?. Clin Chest Med 2018; 39 (04) 669-676
3 Cazzola M, Matera MG, Pezzuto G. Inflammation – a new therapeutic target in pneumonia. Respiration 2005; 72 (02) 117-126
4 Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol 2017; 237: 171-196
5 Huang L, Gao X, Chen M. Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial. J Trop Pediatr 2014; 60 (05) 338-342
6 Bozzette SA, Sattler FR, Chiu J. et al; California Collaborative Treatment Group. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323 (21) 1451-1457
7 Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2: CD010406
8 Marti C, Grosgurin O, Harbarth S. et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One 2015; 10 (12) e0144032
9 Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. N Engl J Med 2020; 383 (18) 1757-1766
10 Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med 2020; 383 (25) 2451-2460
11 Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020; 39 (07) 2085-2094
12 Chalmers JD, Crichton ML, Goeminne PC. et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J 2021; 57 (04) 2100048
13 van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P. et al. A guide to immunotherapy for COVID-19. Nat Med 2022; 28 (01) 39-50
14 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
15 Wittermans E, Vestjens SMT, Spoorenberg SMC. et al; Santeon-CAP Study Group, Members of the Santeon-CAP Study Group. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J 2021; 58 (02) 2002535
16 Torres A, Sibila O, Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (07) 677-686
17 Blum CA, Nigro N, Briel M. et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015; 385 (9977): 1511-1518
18 Meijvis SCA, Hardeman H, Remmelts HHF. et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377 (9782): 2023-2030
19 Fernández-Serrano S, Dorca J, Garcia-Vidal C. et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15 (02) R96
20 Snijders D, Daniels JMA, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181 (09) 975-982
21 Mikami K, Suzuki M, Kitagawa H. et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007; 185 (05) 249-255
22 Confalonieri M, Urbino R, Potena A. et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171 (03) 242-248
23 Briel M, Spoorenberg SMC, Snijders D. et al; Ovidius Study Group, Capisce Study Group, STEP Study Group. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data meta-analysis. Clin Infect Dis 2018; 66 (03) 346-354
24 Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017; 12: CD007720
25 Wu WF, Fang Q, He GJ. Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. Am J Emerg Med 2018; 36 (02) 179-184
26 Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 2016; 149 (01) 209-219
27 Diaz E, Martin-Loeches I, Canadell L. et al; H1N1 SEMICYUC-CIBERES-REIPI Working Group (GETGAG). Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012; 64 (03) 311-318
28 Siemieniuk RAC, Meade MO, Alonso-Coello P. et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 2015; 163 (07) 519-528
29 Lee N, Wong CK, Chan PKS. et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One 2011; 6 (10) e26050
30 Quispe-Laime AM, Bracco JD, Barberio PA. et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010; 36 (01) 33-41
31 Liem NT, Tung CV, Hien ND. et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009; 48 (12) 1639-1646
32 Brun-Buisson C, Richard JCM, Mercat A, Thiébaut ACM, Brochard L. REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183 (09) 1200-1206
33 Wirz SA, Blum CA, Schuetz P. et al; STEP Study Group. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. Eur Respir J 2016; 48 (04) 1150-1159
34 Zhang Y, Sun W, Svendsen ER. et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. Crit Care 2015; 19: 46
35 Yang JW, Fan LC, Miao XY. et al. Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. Clin Microbiol Infect 2015; 21 (10) 956-963
36 Villar J, Ferrando C, Martínez D. et al; dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 8 (03) 267-276
37 Tongyoo S, Permpikul C, Mongkolpun W. et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 2016; 20 (01) 329
38 Meduri GU, Golden E, Freire AX. et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131 (04) 954-963
39 Steinberg KP, Hudson LD, Goodman RB. et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354 (16) 1671-1684
40 Meduri GU, Headley AS, Golden E. et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998; 280 (02) 159-165
41 Bernard GR, Luce JM, Sprung CL. et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317 (25) 1565-1570
42 Villar J, Belda J, Añón JM. et al; DEXA-ARDS Network. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial. Trials 2016; 17: 342
43 Guan W-J, Ni Z-Y, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
44 Lauer SA, Grantz KH, Bi Q. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172 (09) 577-582
45 Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med 2020; 173 (05) 362-367
46 Yin X, Riva L, Pu Y. et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep 2021; 34 (02) 108628
47 Hadjadj J, Yatim N, Barnabei L. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020; 369 (6504): 718-724
48 Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med 2021; 27 (01) 28-33
49 Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 2021; 97 (1147): 312-320
50 Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options. Microb Pathog 2021; 150: 104673
51 Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324 (08) 782-793
52 Tan LY, Komarasamy TV, Rmt Balasubramaniam V. Hyperinflammatory immune response and COVID-19: a double edged sword. Front Immunol 2021; 12: 742941
53 Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science 2022; 375 (6585): 1122-1127
54 Tonutti A, Motta F, Ceribelli A, Isailovic N, Selmi C, De Santis M. Anti-MDA5 antibody linking COVID-19, type I interferon, and autoimmunity: a case report and systematic literature review. Front Immunol 2022; 13: 937667
55 Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383 (23) 2255-2273
56 Rodríguez Y, Novelli L, Rojas M. et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun 2020; 114: 102506
57 Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol 2021; 33 (05) 419-430
58 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033-1034
59 Zhang W, Qin C, Fei Y. et al. Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. Clin Immunol 2022; 239: 109022
60 Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 2005; 353 (16) 1711-1723
61 Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011; 335 (01) 2-13
62 Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci 2019; 40 (01) 38-49
63 Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000; 356 (9224): 87-89
64 Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44 (01) 61-98
65 Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002; 165 (07) 983-991
66 Wagner C, Griesel M, Mikolajewska A. et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8: CD014963
67 Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39 (05) 405-407
68 Wang X, Jehi L, Ji X, Mazzone PJ. Phenotypes and subphenotypes of patients with COVID-19: a latent class modeling analysis. Chest 2021; 159 (06) 2191-2204
69 Ranard BL, Megjhani M, Terilli K. et al. Identification of endotypes of hospitalized COVID-19 patients. Front Med (Lausanne) 2021; 8: 770343
70 Ranjeva S, Pinciroli R, Hodell E. et al. Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019. EClinicalMedicine 2021; 34: 100829
71 Amati F, Dela Cruz CS. One size does not fit all: moving towards a personalized approach for steroids in COVID-19. Chest 2021; 159 (05) 1693-1695
72 Chen H, Xie J, Su N. et al. Corticosteroid therapy is associated with improved outcome in critically ill patients with COVID-19 with hyperinflammatory phenotype. Chest 2021; 159 (05) 1793-1802
73 Agusti A, Bel E, Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47 (02) 410-419
74 Liu Y, Li Y, Xu D, Zhang J, Peng Z. Severe COVID-19: immunosuppression or hyperinflammation?. Shock 2021; 56 (02) 188-199
75 Papadopoulou C, Al Obaidi M, Moraitis E, Compeyrot-Lacassagne S, Eleftheriou D, Brogan P. Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist. Rheumatology (Oxford) 2021; 60 (02) 911-917
76 Akter F, Araf Y, Hosen MJ. Corticosteroids for COVID-19: worth it or not?. Mol Biol Rep 2022; 49 (01) 567-576
77 Ghanei M, Solaymani-Dodaran M, Qazvini A. et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res 2021; 22 (01) 245
78 Horby P, Lim WS, Emberson JR. et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384 (08) 693-704
79 Tomazini BM, Maia IS, Cavalcanti AB. et al; COALITION COVID-19 Brazil III Investigators. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 2020; 324 (13) 1307-1316
80 Angus DC, Derde L, Al-Beidh F. et al; Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020; 324 (13) 1317-1329
81 Edalatifard M, Akhtari M, Salehi M. et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J 2020; 56 (06) 2002808
82 Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F. et al; GLUCOCOVID investigators. Methylprednisolone in adults hospitalized with COVID-19 pneumonia : an open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr 2021; 133 (7-8): 303-311
83 Les I, Loureiro-Amigo J, Capdevila F. et al. Methylprednisolone pulses in hospitalized COVID-19 patients without respiratory failure: a randomized controlled trial. Front Med (Lausanne) 2022; 9: 807981
84 Maskin LP, Bonelli I, Olarte GL. et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomized open-label clinical trial. J Intensive Care Med 2022; 37 (04) 491-499
85 Toroghi N, Abbasian L, Nourian A. et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacol Rep 2022; 74 (01) 229-240
86 Munch MW, Myatra SN, Vijayaraghavan BKT. et al; COVID STEROID 2 Trial Group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA 2021; 326 (18) 1807-1817
87 Munch MW, Meyhoff TS, Helleberg M. et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiol Scand 2021; 65 (10) 1421-1430
88 Jeronimo CMP, Farias MEL, Val FFA. et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2021; 72 (09) e373-e381
89 Dequin PF, Heming N, Meziani F. et al; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA 2020; 324 (13) 1298-1306
90 Tang X, Feng YM, Ni JX. et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial. Respiration 2021; 100 (02) 116-126
91 Ranjbar K, Moghadami M, Mirahmadizadeh A. et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21 (01) 337
92 Sinha P, Furfaro D, Cummings MJ. et al. Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. Am J Respir Crit Care Med 2021; 204 (11) 1274-1285
93 Odeyemi YE, Chalmers SJ, Barreto EF, Jentzer JC, Gajic O, Yadav H. Early, biomarker-guided steroid dosing in COVID-19 pneumonia: a pilot randomized controlled trial. Crit Care 2022; 26 (01) 9
94 Granholm A, Kjær MN, Munch MW. et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med 2022; 48 (05) 580-589
95 Liu D, Ahmet A, Ward L. et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013; 9 (01) 30
96 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
97 COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020. (National Institute for Health and Care Excellence: Clinical Guidelines). Accessed May 09, 2022, at: http://www.ncbi.nlm.nih.gov/books/NBK567261/
98 Bivona G, Agnello L, Ciaccio M. Biomarkers for prognosis and treatment response in COVID-19 patients. Ann Lab Med 2021; 41 (06) 540-548
99 Gudigar A, Raghavendra U, Nayak S. et al. Role of artificial intelligence in COVID-19 detection. Sensors (Basel) 2021; 21 (23) 8045
100 Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 2016; 42 (01) 157-176 , ix–x